654 related articles for article (PubMed ID: 24262879)
1. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
2. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
3. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract][Full Text] [Related]
4. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
6. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
7. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
8. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract][Full Text] [Related]
9. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
13. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
[TBL] [Abstract][Full Text] [Related]
15. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
16. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
17. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
18. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
20. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
